Skip to main content

Advertisement

SpringerLink
Log in

Bendamustine salvage therapy for T cell neoplasms

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3–4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1–18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89(11):3909–3918

    Google Scholar 

  2. Dodero A, Spina F, Narni F et al (2012) Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3):520–526

    Article  PubMed  CAS  Google Scholar 

  3. Hosing C, Champlin RE (2011) Stem-cell transplantation in T cell non-Hodgkin’s lymphomas. Ann Oncol 22(7):1471–1477

    Article  PubMed  CAS  Google Scholar 

  4. Knauf WU, Lissitchkov T, Aldaoud A et al (2012) Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 159(1):67–77. doi:10.1111/bjh.12000, Epub 2012 Aug 4

    Article  PubMed  CAS  Google Scholar 

  5. Fischer K, Cramer P, Busch R et al (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29(26):3559–3566

    Article  PubMed  CAS  Google Scholar 

  6. Fischer K, Cramer P, Busch R et al (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase ii trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30(26):3209–3216. doi:10.1200/JCO.2011.39.2688, Epub 2012 Aug 6

    Article  PubMed  CAS  Google Scholar 

  7. Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 23(15):3383–3389

    Article  PubMed  CAS  Google Scholar 

  8. Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 26(27):4473–4479

    Article  PubMed  CAS  Google Scholar 

  9. Ohmachi K, Ando K, Ogura M et al (2010) Multicenter phase II study of bendamustine for relapsed or refractory indolent B cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059–2064

    Article  PubMed  CAS  Google Scholar 

  10. Kahl BS, Bartlett NL, Leonard JP et al (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116(1):106–114

    PubMed  CAS  Google Scholar 

  11. Damaj G, Gressin R, Bouabdallah K et al (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T cell lymphomas: the BENTLY trial. J Clin Oncol 31(1):104–10. doi:10.1200/JCO.2012.43.7285, Epub 2012 Oct 29

    Article  PubMed  CAS  Google Scholar 

  12. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  13. Olsen EA, Whittaker S, Kim YH et al (2011) Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29(18):2598–2607

    Article  PubMed  Google Scholar 

  14. Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190–2196

    Article  PubMed  CAS  Google Scholar 

  15. O’Connor OA, Pro B, Pinter-Brown L et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182–1189

    Article  PubMed  Google Scholar 

  16. Piekarz RL, Frye R, Turner M et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T cell lymphoma. J Clin Oncol 27(32):5410–5417

    Article  PubMed  CAS  Google Scholar 

  17. Piekarz RL, Frye R, Prince HM et al (2011) Phase 2 trial of romidepsin in patients with peripheral T cell lymphoma. Blood 117(22):5827–5834

    Article  PubMed  CAS  Google Scholar 

  18. Coiffier B, Pro B, Prince HM et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631–636

    Article  PubMed  CAS  Google Scholar 

  19. Dueck G, Chua N, Prasad A et al (2010) Interim report of a phase 2 clinical trial of lenalidomide for T cell non-Hodgkin lymphoma. Cancer 116:4541–4548

    Article  PubMed  CAS  Google Scholar 

  20. Friedberg J, Mahadevan D, Jung JA et al (2011) Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B an T cell non-Hodgkin lymphoma (NHL) [Abstract]. Blood 118(46):Abs95

    Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Clinica Ematologica, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, p.le S. Maria Misericordia 15, 33100, Udine, Italy

    Francesco Zaja, Stefano Volpetti & Renato Fanin

  2. UOC di Ematologia/CTMO, Fondazione IRCS, Cà Granda OM, Policlinico, Università degli Studi, Milan, Italy

    Luca Baldini & Maria Goldaniga

  3. Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy

    Andrés J. M. Ferreri

  4. Dipartimento di Medicina Diagnostica, Clinica e Sanità pubblica. Centro Oncologico Modenese, Università di Modena e Reggio Emilia, Modena, Italy

    Stefano Luminari

  5. Divisione di Ematologia, IFCA, Firenze, Italy

    Alberto Grossi

  6. DPT Ematologia Ospedale SS Antonio e Biagio, Alessandria, Italy

    Flavia Salvi

  7. Clinica Ematologica, Dipartimento di Ematologia ed Immunologia, Università degli Studi, Padova, Italy

    Renato Zambello

Authors
  1. Francesco Zaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Baldini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrés J. M. Ferreri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefano Luminari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alberto Grossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Flavia Salvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Renato Zambello
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Goldaniga
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Stefano Volpetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Renato Fanin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Zaja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zaja, F., Baldini, L., Ferreri, A.J.M. et al. Bendamustine salvage therapy for T cell neoplasms. Ann Hematol 92, 1249–1254 (2013). https://doi.org/10.1007/s00277-013-1746-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1746-9

Keywords

Search

Navigation